新型受控代谢加速剂HU6治疗肥胖相关射血分数保留的心力衰竭:HuMAIN-HFpEF随机临床试验
HuMAIN-HFpEF是一项多中心、剂量递增、双盲、安慰剂对照的2A期探索性随机临床试验,纳入66例慢性稳定HFpEF合并肥胖患者,评估HU6(一种新型线粒体解偶联剂)治疗19周(150 mg/日起,可滴定至450 mg/日)的疗效与安全性。但峰值VO2、6分钟步行距离、KCCQ评分、hs-CRP、NT-proBNP及舒张功能均无显著变化。
要点
- 峰值VO2、6分钟步行距离、KCCQ评分及舒张功能等均无显著改善。
- 不良事件与安慰剂组相似,严重不良事件均判定与治疗无关。
核心结论
- 在肥胖相关HFpEF患者中,HU6治疗19周导致适度但具有统计学意义的体重下降,但峰值VO2无显著变化。
- 需要更大规模、更长疗程的试验来确定长期HU6治疗能否改善运动功能、生活质量和心血管结局。
研究设计与样本
- HuMAIN-HFpEF为多中心、双盲、安慰剂对照、剂量递增的2A期探索性随机临床试验。
- 共随机66例慢性稳定HFpEF合并肥胖患者,平均(SD)年龄64.5(12)岁,女性38例(58%),平均(SD)体重110.9(22.4)kg。
- 56例完成试验;数据分析时间为2024年7月至10月。
主要发现
- 峰值VO2、6分钟步行距离、堪萨斯城心肌病问卷评分、高敏C反应蛋白、N末端脑钠肽前体及舒张功能均无统计学显著变化。
- 严重不良事件见于5例参与者(HU6组4例,安慰剂组1例),包括1例死亡,均判定与治疗无关。
关键数值与推荐
- HU6治疗19周,起始剂量150 mg/日,根据安全性和耐受性可上调至450 mg/日。
临床怎么用
- HU6可能作为肥胖相关HFpEF患者的减重策略之一,但当前证据未显示其改善运动能力或症状。
- 需等待更大规模、更长疗程的试验结果,再考虑临床应用。
局限性
- 本研究为2A期探索性试验,样本量较小(66例随机,56例完成)。
- 治疗时长仅19周,无法评估长期心血管结局。
- 峰值VO2等关键次要终点无显著改善,提示单纯减重未必转化为功能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss. OBJECTIVE: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF. DESIGN, SETTING, AND PARTICIPANTS: The Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for Subjects With Obese HFpEF (HuMAIN-HFpEF) trial was a multicenter, dose-escalation randomized clinical trial among patients with chronic stable HFpEF and obesity. Data were analyzed from July to October 2024. INTERVENTION: HU6 treatment for 19 weeks, starting at 150 mg per day and potentially up titrated to 450 mg per day based on safety and tolerability vs placebo. MAIN OUTCOMES AND MEASURES: The primary end point was change in body weight. RESULTS: Of 66 participants randomized (mean [SD] age, 64.5 [12] years; 38 female [58%]; mean [SD] weight, 110.9 [22.4] kg), 56 completed the trial. HU6 (vs placebo) significantly decreased weight (between-group difference, -2.86 kg; 95% CI, -4.68 to -1.04 kg; P = .003), total fat mass (between-group difference, -2.96 kg; 95% CI, -4.50 to -1.42 kg; P < .001), and percentage visceral fat (between-group difference,-1.3%; 95% CI, -2.1 to -0.5%; P = .003), with no significant loss of muscle mass. There were no statistically significant changes in peak VO2, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, high-sensitivity C-reactive protein level, N-terminal pro-brain natriuretic peptide level, or diastolic function. Serious adverse events were noted in 5 participants (4 in the HU6 group; 1 in the placebo group), including 1 death, all judged unrelated to treatment. CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05284617.
引用
- Pandey A, Lewis GD, Borlaug BA, et al. Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40072462. doi:10.1001/jamacardio.2025.0103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。